PL439809A1 - Metody wytwarzania przeciwciała anty-alfa4beta7 - Google Patents
Metody wytwarzania przeciwciała anty-alfa4beta7Info
- Publication number
- PL439809A1 PL439809A1 PL439809A PL43980920A PL439809A1 PL 439809 A1 PL439809 A1 PL 439809A1 PL 439809 A PL439809 A PL 439809A PL 43980920 A PL43980920 A PL 43980920A PL 439809 A1 PL439809 A1 PL 439809A1
- Authority
- PL
- Poland
- Prior art keywords
- antibody
- methods
- vedolizumab
- making anti
- integrin antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962859494P | 2019-06-10 | 2019-06-10 | |
| PCT/US2020/037059 WO2020252069A1 (en) | 2019-06-10 | 2020-06-10 | METHODS OF PRODUCING AN ANTI-α4β7 ANTIBODY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL439809A1 true PL439809A1 (pl) | 2022-12-05 |
Family
ID=73781728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL439809A PL439809A1 (pl) | 2019-06-10 | 2020-06-10 | Metody wytwarzania przeciwciała anty-alfa4beta7 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220267449A1 (https=) |
| EP (1) | EP3980466A4 (https=) |
| JP (2) | JP7624414B2 (https=) |
| CN (3) | CN114375307B (https=) |
| AR (1) | AR119270A1 (https=) |
| AU (1) | AU2020290943A1 (https=) |
| BR (1) | BR112021024897A2 (https=) |
| CA (1) | CA3143167A1 (https=) |
| IL (1) | IL288825A (https=) |
| MA (1) | MA56129A (https=) |
| MX (1) | MX2021015300A (https=) |
| PL (1) | PL439809A1 (https=) |
| TW (1) | TW202112818A (https=) |
| WO (1) | WO2020252069A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12433947B2 (en) | 2018-04-10 | 2025-10-07 | Dr. Reddy's Laboratories Limited | Stable formulations of therapeutic antibody |
| WO2019198099A1 (en) * | 2018-04-10 | 2019-10-17 | Dr. Reddy's Laboratories Limited | Stable antibody formulation |
| WO2023007516A1 (en) * | 2021-07-29 | 2023-02-02 | Dr. Reddy’S Laboratories Limited | Method to control high molecular weight aggregates in an antibody composition |
| EP4380948A4 (en) * | 2021-08-05 | 2025-07-16 | Dr Reddys Laboratories Ltd | METHOD FOR PURIFYING AN ANTIBODY COMPOSITION BY MEANS OF CATION EXCHANGE CHROMATOGRAPHY |
| WO2023031965A1 (en) * | 2021-09-03 | 2023-03-09 | Dr. Reddy’S Laboratories Limited | Method to obtain a purified antibody composition |
| WO2024233992A2 (en) * | 2023-05-11 | 2024-11-14 | Trophogen, Inc. | Methods of manufacturing highly glycosylated glycoprotein hormones and their analogs |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5429746A (en) * | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| WO2014142882A1 (en) * | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Protein purification using displacement chromatography |
| PL3116891T3 (pl) * | 2014-03-10 | 2020-07-27 | Richter Gedeon Nyrt. | Oczyszczanie immunoglobuliny z zastosowaniem etapów wstępnego oczyszczania |
| MA41636A (fr) * | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | Méthode de traitement de la cholangite sclérosante primitive |
-
2020
- 2020-06-10 CN CN202080049572.2A patent/CN114375307B/zh active Active
- 2020-06-10 WO PCT/US2020/037059 patent/WO2020252069A1/en not_active Ceased
- 2020-06-10 MX MX2021015300A patent/MX2021015300A/es unknown
- 2020-06-10 CA CA3143167A patent/CA3143167A1/en active Pending
- 2020-06-10 BR BR112021024897A patent/BR112021024897A2/pt unknown
- 2020-06-10 CN CN202510051206.5A patent/CN119859188A/zh active Pending
- 2020-06-10 TW TW109119563A patent/TW202112818A/zh unknown
- 2020-06-10 JP JP2021573298A patent/JP7624414B2/ja active Active
- 2020-06-10 CN CN202511678992.8A patent/CN121736106A/zh active Pending
- 2020-06-10 AR ARP200101641A patent/AR119270A1/es unknown
- 2020-06-10 AU AU2020290943A patent/AU2020290943A1/en active Pending
- 2020-06-10 US US17/596,421 patent/US20220267449A1/en active Pending
- 2020-06-10 PL PL439809A patent/PL439809A1/pl unknown
- 2020-06-10 EP EP20822340.4A patent/EP3980466A4/en active Pending
- 2020-06-10 MA MA056129A patent/MA56129A/fr unknown
-
2021
- 2021-12-09 IL IL288825A patent/IL288825A/en unknown
-
2024
- 2024-12-13 JP JP2024218770A patent/JP2025063035A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114375307B (zh) | 2025-12-05 |
| BR112021024897A2 (pt) | 2022-01-18 |
| CN121736106A (zh) | 2026-03-27 |
| TW202112818A (zh) | 2021-04-01 |
| EP3980466A4 (en) | 2023-06-07 |
| WO2020252069A1 (en) | 2020-12-17 |
| JP7624414B2 (ja) | 2025-01-30 |
| CA3143167A1 (en) | 2020-12-17 |
| CN119859188A (zh) | 2025-04-22 |
| US20220267449A1 (en) | 2022-08-25 |
| EP3980466A1 (en) | 2022-04-13 |
| JP2025063035A (ja) | 2025-04-15 |
| MX2021015300A (es) | 2022-02-03 |
| AU2020290943A1 (en) | 2022-02-03 |
| JP2022536486A (ja) | 2022-08-17 |
| CN114375307A (zh) | 2022-04-19 |
| AR119270A1 (es) | 2021-12-09 |
| MA56129A (fr) | 2022-04-13 |
| IL288825A (en) | 2022-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL439809A1 (pl) | Metody wytwarzania przeciwciała anty-alfa4beta7 | |
| RU2768003C2 (ru) | Интегрированное непрерывное производство терапевтических белковых лекарственных веществ | |
| AR122348A2 (es) | Métodos y composiciones para tolerancia a herbicidas en plantas | |
| ZA202002617B (en) | Methods and compositions for ppo herbicide tolerance | |
| BR112017023912A2 (pt) | sistema modular e processo para produção contínua e/ou processamento de um produto de forma desinfectada | |
| PH12020500027A1 (en) | Purification of iduronate-2-sulfatase | |
| BR112021024848A2 (pt) | Métodos de purificação de anticorpos e composições dos mesmos | |
| RU2014138499A (ru) | АНТИГЕНСВЯЗЫВАЮЩАЯ МОЛЕКУЛА ДЛЯ УСКОРЕНИЯ ИСЧЕЗНОВЕНИЯ АНТИГЕНА ЧЕРЕЗ FycRIIB | |
| FI20185493A7 (fi) | Menetelmä biologista alkuperää olevan materiaalin puhdistamiseksi | |
| EA202092088A1 (ru) | Антитела анти-phf-тау и их применение | |
| SG157346A1 (en) | Improved purification of collagenases from clostridium histolyticum liquid culture | |
| MX372711B (es) | Metodos para la purificacion de arilsulfatasa a. | |
| ME02882B (me) | Kompozicije i postupci za proizvodnju glikoproteina | |
| EP3980068A4 (en) | CELL CULTURE METHODS AND COMPOSITIONS FOR THE PRODUCTION OF ANTIBODIES | |
| UA115235C2 (uk) | Ген токсину axmi335 bacillus thuringiensis та спосіб його застосування | |
| PE20231747A1 (es) | Acido nucleico que codifica una entidad anti-vegf y un regulador del complemento negativo y sus usos para el tratamiento de la degeneracion macular relacionada con la edad | |
| FI3063287T3 (fi) | Monensiinin käyttö rekombinanttiproteiinien glykosylaation säätelyyn | |
| PH12021552001A1 (en) | Producing compositions comprising two or more antibodies | |
| MX2017008633A (es) | Procedimiento para preparar una proteina de fusion tnfr-fc que contiene un contenido objetivo de impurezas. | |
| Poulsen et al. | Mammalian perfusion cultivation at high L-Arginine concentration for efficient production of recombinant protein by increasing perfusion filter transmission | |
| TR2023014436T (tr) | Afi̇ni̇te kromatografi̇si̇ i̇le protei̇n saflaştirilmasi | |
| Allalasandra et al. | Hypoxia Primed Placental Mesenchymal Stem Cells For Wound Healing | |
| Amid | Effects of Extraction, Purification and Freeze Drying Conditions on Enzymatic Properties of Serine Protease from Mango (Mangifera Indica L. Cv. Chokanan) Peel | |
| Roudkenar | Human Plasma Derived Drugs Separation by Fractionation of Plasmawith Polyethylene Glycol | |
| Schiefelbein et al. | frontiers in MINI REVIEW ARTICLE PLANT SCIENCE published: 17 February 2014 |